Quartz·1 min read·easy
Novo Nordisk is raising its full-year outlook as its weight loss pill keeps selling
✦AI Summary
Novo Nordisk has raised its full-year financial outlook due to the strong sales performance of its Wegovy weight loss medication. The drug has surpassed 5 million prescriptions in the United States since its launch.
The Danish drugmaker's Wegovy pill has exceeded 5 million prescriptions in the U.S. since launch, driving stronger-than-expected profit
businesshealtheconomy
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in